Ohcanbohtosat - Deborah K. Armstrong

Aiddostahte ozu
  1. 1
    Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease

    Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease Dahkki Deborah K. Armstrong

    Almmustuhtton 2002
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    New Therapies for Ovarian Cancer

    New Therapies for Ovarian Cancer Dahkki Deborah K. Armstrong

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Recent progress in the diagnosis and treatment of ovarian cancer

    Recent progress in the diagnosis and treatment of ovarian cancer Dahkki Danijela Jelovac, Deborah K. Armstrong

    Almmustuhtton 2011
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Is the Easier Way Ever the Better Way?

    Is the Easier Way Ever the Better Way? Dahkki S. Dennis, Robert E. Bristow, Deborah K. Armstrong, Beth Y. Karlan

    Almmustuhtton 2011
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis.

    Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. Dahkki W. Stratford May, P G Tyler, Takahiko Ito, Deborah K. Armstrong, K A Qatsha, N E Davidson

    Almmustuhtton 1994
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer

    Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer Dahkki Amy L. Gross, Betty J. May, Jennifer E. Axilbund, Deborah K. Armstrong, Richard B.S. Roden, Kala Visvanathan

    Almmustuhtton 2015
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

    Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study Dahkki Lisa M. Landrum, James Java, Cara Mathews, Grainger S. Lanneau, Larry J. Copeland, Deborah K. Armstrong, Joan L. Walker

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Survival in Women With Grade 1 Serous Ovarian Carcinoma

    Survival in Women With Grade 1 Serous Ovarian Carcinoma Dahkki Amanda N. Fader, James Java, Stefanie Ueda, Robert E. Bristow, Deborah K. Armstrong, Michael A. Bookman, David M. Gershenson

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

    Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study Dahkki Devansu Tewari, James Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, John K. Chan

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study

    Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Grou... Dahkki Angeles Alvarez Secord, John A. Blessing, Deborah K. Armstrong, William H. Rodgers, Zoe Miner, Mack N. Barnes, George Lewandowski, Robert S. Mannel

    Almmustuhtton 2008
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Centralization of care for patients with advanced‐stage ovarian cancer

    Centralization of care for patients with advanced‐stage ovarian cancer Dahkki Robert E. Bristow, Antonio Santillan, Teresa Diaz‐Montes, Ginger J. Gardner, Robert Giuntoli, Benjamin C. Meisner, Kevin D. Frick, Deborah K. Armstrong

    Almmustuhtton 2007
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Comparison of Paclitaxel-, 5-Fluoro-2′-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis

    Comparison of Paclitaxel-, 5-Fluoro-2′-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis Dahkki Timothy Kottke, April L. Blajeski, L. Miguel Martins, Peter W. Mesner, Nancy E. Davidson, William C. Earnshaw, Deborah K. Armstrong, Scott H. Kaufmann

    Almmustuhtton 1999
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Relationship Between<i>ERCC1</i>Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer

    Relationship Between<i>ERCC1</i>Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin a... Dahkki Thomas C. Krivak, Kathleen M. Darcy, Chunqiao Tian, Deborah K. Armstrong, Bora Baysal, Holly H. Gallion, Christine B. Ambrosone, Julie A. DeLoia

    Almmustuhtton 2008
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study

    Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study Dahkki Cody Ramin, Betty J. May, Richard B.S. Roden, Mikiaila M. Orellana, Brenna Hogan, Michelle S. McCullough, Dana Petry, Deborah K. Armstrong, Kala Visvanathan

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study

    A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study Dahkki Vivian E. von Gruenigen, Helen Q. Huang, Karen M. Gil, Heidi Gibbons, Bradley J. Monk, Peter G. Rose, Deborah K. Armstrong, David Cella, Lari Wenzel

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials

    Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials Dahkki Vivian E. von Gruenigen, Helen Q. Huang, Karen M. Gil, Heidi Gibbons, Bradley J. Monk, Peter G. Rose, Deborah K. Armstrong, David Cella, Lari Wenzel

    Almmustuhtton 2009
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study

    BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study Dahkki Jamie Lesnock, Kathleen M. Darcy, Chunqiao Tian, Julie A. DeLoia, Melissa M. Thrall, Chris Zahn, Deborah K. Armstrong, Michael J. Birrer, Thomas C. Krivak

    Almmustuhtton 2013
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

    Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer Dahkki Deborah K. Armstrong, Brian N. Bundy, Lari Wenzel, Helen Q. Huang, Rebecca N. Baergen, Shashikant Lele, Larry J. Copeland, Joan L. Walker, Robert A. Burger

    Almmustuhtton 2006
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

    CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers Dahkki Chunqiao Tian, Maurie Markman, Richard J. Zaino, Robert F. Ozols, William P. McGuire, Franco M. Muggia, Peter G. Rose, David R. Spriggs, Deborah K. Armstrong

    Almmustuhtton 2009
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study

    The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study Dahkki Amanda N. Fader, James Java, Thomas C. Krivak, Robert E. Bristow, Ana I. Tergas, Michael A. Bookman, Deborah K. Armstrong, Edward J. Tanner, David M. Gershenson

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: